Gene · 2696
Papers1,380
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,380
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Gene-Diet Interactions in Type 2 Diabetes: A Systematic Review of Observational Studies and Clinical Trials. | Nutrients | 2026 | 42588062 | PubTator, text mining | PubMed |
| From indirect regulation to multi-layered metabolic control in MASLD: Multi-receptor agonism and microbiota-metabolite functional convergence. | Pharmacol Res | 2026 | 42570767 | PubTator, text mining | PubMed |
| The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity. | Pharmacol Res | 2026 | 42556625 | PubTator, text mining | PubMed |
| Identification of allosteric sites and allosteric inhibitors in the glucose-dependent insulinotropic polypeptide receptor via molecular simulations. | Int J Biol Macromol | 2026 | 42537958 | PubTator, text mining | PubMed |
| Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity. | J Comput Aided Mol Des | 2026 | 42530676 | PubTator, text mining | PubMed |
| A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors. | Cureus | 2026 | 42504310 | PubTator, text mining | PubMed |
| Tirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives. | Front Microbiol | 2026 | 42499664 | PubTator, text mining | PubMed |
| One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy. | Appetite | 2026 | 42492687 | PubTator, text mining | PubMed |
| Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response? | J Endocr Soc | 2026 | 42487666 | PubTator, text mining | PubMed |
| Multi-ancestry Transcriptome-Wide Association Study (TWAS)-Informed Prioritization of Antipsychotic Metabolic Risk: Evaluation of GLP1R as a Shared Mechanistic Link. | Cureus | 2026 | 42465707 | PubTator, text mining | PubMed |
| Opposing GIPR brainstem circuits differentially control feeding behaviour. | bioRxiv | 2026 | 42465481 | PubTator, text mining | PubMed |
| β-arrestin and myosin VI cooperatively control glucose-dependent insulinotropic peptide receptor (GIPR) internalization and signaling dynamics. | J Biol Chem | 2026 | 42463051 | PubTator, text mining | PubMed |
| Discovery of Biased Dual-Agonists of Glucagon-Like Peptide 1 and Glucagon Receptors through Mutation of a Conserved Aspartate. | ACS Med Chem Lett | 2026 | 42445014 | PubTator, text mining | PubMed |
| Identification of glicentin as a low-potency glucose-dependent insulinotropic polypeptide receptor agonist. | Peptides | 2026 | 42425317 | PubTator, text mining | PubMed |
| GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways. | Cell Chem Biol | 2026 | 42419304 | PubTator, text mining | PubMed |
| Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial. | JACC Heart Fail | 2026 | 42417681 | PubTator, text mining | PubMed |
| Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series. | Headache | 2026 | 42403198 | PubTator, text mining | PubMed |
| GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies. | Pharmacol Res | 2026 | 42379432 | PubTator, text mining | PubMed |
| Molecular Basis of Synergistic Causal Effect of Dual GLP-1R and GIPR Agonists for Risk Reduction in Diabetic Retinopathy, Alzheimer Disease, and Coronary Artery Disease in Diabetic Patients. | Genes (Basel) | 2026 | 42353761 | PubTator, text mining | PubMed |
| Targeting the Crosstalk Between Metabolism and Chronic Inflammation: In Silico Multitargeting Drug Design Approach for Cardiometabolic Syndrome. | Biomedicines | 2026 | 42351639 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2696/papers?page=2